Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRAE’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRAE
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Daniel ROSENBERG

Professor and Investigator, Center for Molecular Oncology

Uconn Health, Uconn School of Medicine, Center for Molecular Oncology Connecticut, USA

Dr. Daniel W. Rosenberg obtained his Doctoral Degree in Environmental Health Sciences at the University of Michigan. He began his research career in molecular pharmacology at The Rockefeller University in the Laboratory of Attallah Kappas, where he attained the rank of Assistant Professor. After moving to the University of Connecticut in 1991, he was appointed as the HealthNet, Inc. Chair in Cancer Biology and Professor of Medicine in the School of Medicine. He has developed an active research program that focuses on the pathogenesis of gastrointestinal diseases and has also established a translational research program in Colon Cancer Prevention, serving as its Director. The long‐term goals of the Program are to improve the early detection of cancer, develop population‐based studies of cancer risk and develop effective chemoprevention strategies for the treatment of high‐risk individuals. Dr. Rosenberg has published a number of recent papers that define the epigenetics of early human neoplasia in the colon, as well as the mutational, transcriptional and microbiome profiles that are associated with neoplastic progression. Research in the Rosenberg Lab extends across a wide range of research topics in colon cancer biology, applying sophisticated mouse genetic cancer models to further our understanding of carcinogenic mechanisms and to identify novel chemoprevention strategies. He is particularly interested in how nutrition influences cancer risk via changes to the microbiome, thereby affecting colonic homeostasis both in healthy and diseased tissues. As part of his nutritional-cancer approach, his lab has a particular interest in how prostaglandins and one-carbon metabolism may be therapeutically targeted for providing durable cancer prevention.

 

Dr. Daniel Rosenberg’s talk will focus on the use of laser capture microdissection to characterize the stromal-epithelial interactions that drive early colonic neoplasia in humans and mice. He will also present how LCM can be used to capture small numbers of colonic crypt stem cells defined by specific immunological markers and how these stem cell populations acquire somatic mutations and respond to specific environmental challenges (microbiome, inflammatory).